

WEST Search History

DATE: Monday, September 29, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT; PLUR=YES; OP=OR</i>			
L4	L2 and exendin	7	L4
L3	L2 and glucagon	231	L3
L2	memory or learning or cognition	432284	L2
L1	gilatide	0	L1

END OF SEARCH HISTORY

=> d his

(FILE 'HOME' ENTERED AT 10:38:23 ON 29 SEP 2003)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 10:38:37 ON 29 SEP 2003

L1	966 S GLACAGON OR EXENDIN
L2	102695 S GLUCAGON OR EXENDIN
L3	336650 S L2 AND MEMORY OR LEARNING OR COGNITION
L4	557198 S MEMORY OR LEARNING OR COGNITION
L5	1157 S L4 AND GLUCAGON OR EXENDIN
L6	2 S L5 AND GILATIDE
L7	3 S GILATIDE

Db 1 HSEGTFTSD 9

RESULT 4

AAW39338
ID AAW39338 standard; peptide; 30 AA.

AC AAW39338;

XX 25-MAR-2003 (updated)

DT 05-JUN-1998 (first entry)

DE H. horridum extendin-3 peptide derivative #7.

XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

OS Heloderma horridum.

PH Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX WO9746384-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP02930.

XX 05-JUN-1996; 96DE-1022502.

XX 13-SEP-1996; 96DE-1037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Goetze B, Goetze R, Hoffmann E;

XX WPI; 1998-042119/04.

XX Truncated versions of extendin peptide(s) for treating diabetes -

PT increase secretion and biosynthesis of insulin, but reduce those of

PT glucagon, and do not induce hypoglycaemia

XX Claim 2; Page 26; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4

CC isolated from Heloderma horridum which are used in a novel method

CC for the treatment of diabetes mellitus. These peptides can stimulate

CC biosynthesis and secretion of insulin, but have the opposite effect on

CC glucagon, and independent of this activity can increase peripheral

CC glucose utilisation. Extendin-3 and extendin-4 are only active when blood

CC sugar levels are high, so they will not induce hypoglycaemia. Compared

CC with glucagon-like peptide 1 (GLP1) and the known extendins, they are

CC more active (effective at lower doses), more stable to degradation and

CC metabolism and have a longer lasting effect. Truncated forms of this

CC peptide can be made more economically than full length versions.

CC (Updated on 25-MAR-2003 to correct PR field.)

XX Sequence 30 AA;

SQ Query Match 100.0%; Score 49; DB 19; Length 30;

Best Local Similarity 100.0%; Pred. No. 0.036;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HSEGTFTSD 9

DB 1 HSEGTFTSD 9

RESULT 5

AAW39331

ID AAW39331 standard; peptide; 30 AA.

XX

AC AAW39331;

XX 25-MAR-2003 (updated)

DT 05-JUN-1998 (first entry)

XX H. horridum extendin-4 peptide derivative #25.

DE Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

OS Heloderma horridum.

PH Key Location/Qualifiers

FT Modified-site 14

FT /label= Nle

FT /note= "norleucine"

FT Modified-site 30

FT /note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP02930.

XX 05-JUN-1996; 96DE-1022502.

XX 13-SEP-1996; 96DE-1037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Goetze B, Goetze R, Hoffmann E;

XX WPI; 1998-042119/04.

XX Truncated versions of extendin peptide(s) for treating diabetes -

PT increase secretion and biosynthesis of insulin, but reduce those of

PT glucagon, and do not induce hypoglycaemia

XX Claim 2; Page 25; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4

CC isolated from Heloderma horridum which are used in a novel method

CC for the treatment of diabetes mellitus. These peptides can stimulate

CC biosynthesis and secretion of insulin, but have the opposite effect on

CC glucagon, and independent of this activity can increase peripheral

CC glucose utilisation. Extendin-3 and extendin-4 are only active when blood

CC sugar levels are high, so they will not induce hypoglycaemia. Compared

CC with glucagon-like peptide 1 (GLP1) and the known extendins, they are

CC more active (effective at lower doses), more stable to degradation and

CC metabolism and have a longer lasting effect. Truncated forms of this

CC peptide can be made more economically than full length versions.

CC (Updated on 25-MAR-2003 to correct PR field.)

XX Sequence 30 AA;

SQ Query Match 100.0%; Score 49; DB 19; Length 30;

Best Local Similarity 100.0%; Pred. No. 0.036;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HSEGTFTSD 9

DB 1 HSEGTFTSD 9

RESULT 6

AAG63289

ID AAG63289 standard; protein; 30 AA.

XX

XX AAG63289;

XX 01-OCT-2001 (first entry)

XX An insoluble glucagon-like peptide 1 (GLP-1) compound.

DE